Anticorps Recombinant de lapin anti-CD134/OX40

CD134/OX40 Recombinant Antibody for FC

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain

Applications

FC

Conjugaison

Non conjugué

CloneNo.

241398G7

N° de cat : 98181-1-RR

Synonymes

TNFRSF4, OX40L receptor, OX40, CD134, ACT35 antigen



Applications testées

Résultats positifs en cytométriePHA treated human PBMCs,

Dilution recommandée

ApplicationDilution
This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, check data in validation data gallery

Informations sur le produit

98181-1-RR cible CD134/OX40 dans les applications de FC et montre une réactivité avec des échantillons Humain

Réactivité Humain
Hôte / Isotype Lapin / IgG
Clonalité Recombinant
Type Anticorps
Immunogène Protéine recombinante
Nom complet tumor necrosis factor receptor superfamily, member 4
Masse moléculaire calculée 29 kDa
Numéro d’acquisition GenBankNM_003327
Symbole du gène CD134
Identification du gène (NCBI) 7293
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Protein A purfication
Tampon de stockage PBS with 0.09% sodium azide
Conditions de stockageStore at 2 - 8°C. Stable for one year after shipment.

Informations générales

CD134, also known as OX40 and TNFRSF4, is a member of the TNFR-superfamily of receptors (PMID: 2828930; 9766631). It is a type I transmembrane protein predominantly expressed on activated T cells which include CD4 and CD8 T cells, Th2, Th1, and Th17 cells, as well as regulatory T cells (Tregs) (PMID: 20307208). CD134 is activated by its cognate ligand CD134L (OX40L) and functions as a T cell co-stimulatory molecule (PMID: 26215166). CD134-CD134L interactions have been proposed as a potential therapeutic target for treating autoimmune diseases, cancer and infectious disease (PMID: 26215166; 19426222).

Protocole

Product Specific Protocols
FC protocol for CD134/OX40 antibody 98181-1-RRDownload protocol
Standard Protocols
Click here to view our Standard Protocols
{{ptg:RelatedPrimaryAntibodies}}